

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID1220]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final appraisal determination

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equalities issues were identified during the scoping process.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No potential equality issues were raised in any submissions during the appraisal.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

The committee noted that other appraisals in the same disease area had included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC. This is reflected in recommendations 1.3 and 1.4.
--

Tofacitinib is an oral therapy and so may be more easily administered than several of its comparators, which are administered subcutaneously.

However, because the committee recommended tofacitinib, this is not an equalities issue.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The committee noted that other appraisals in the same disease area had included recommendations that healthcare professionals should take into account skin colour/physical, sensory or learning disabilities or communication difficulties when using the PASI/PsARC. The equalities consideration are discussed in section 3.14 of the FAD, and are reflected in recommendations 1.3 and 1.4.

Approved by Associate Director (name): Jasdeep Hayre

Date: 31/07/2018